Member Info for semantic

This is another interesting question, how/why should shareholders be valued and what does that mean?

From one perspective as all the shares are already issued does it matter who owns them? If you think it does, please share your thoughts. This idea goes to the heart of the problem, there was virtually zero interest whenever the company attempted to raise money through a placing, existing shareholders had no interest or complain they were locked out - now the shares are at an all time low, it would appear that no existing shareholders are buying. The placing couldn't have happened with the substantial support of the major shareholder (who paid much higher than the current price). So how should the Company value shareholders who don't want to participate in funding?

Tyke, you could also test my assumption that the majority of posters here are sellers and not buyers or long term committed investors. How else to explain the preoccupation with PR and more communication. None of this has the slightest relevance to the investment case and operations, but would be of interest if you were a potential seller. I expect most here are 'stale bulls', hence the lack of interest in serious investment discussion (there are a couple of exceptions), ditto the day to day, year to year, share price, This has zero relevance to, for example the ultimate value of the GaM project or how widely FTB and other technologies are ultimately adopted

On Friday there were three trades with a total value of £438.95, and the capital value of the Company declined 9%. This is not at all unusual. Excluding the two largest holders, the balance is worth £1.1m at the current market price. Imagine you are an investor screening for a medical company on the Standard list and you come across IB, read everything, look at the chart, and see the whole is currently valued at £1.6m. What view are you likely to adopt? As a thought experiment I acted as this mystery shopper today, to try to gain some insights, trying to be ruthlessly objective - my conclusion is that the mystery shopper will end up mystified.

Tyke, I imagine that the myriad rules, restrictions, confidentialities, ethical requirements and close periods required by the FDA, FCA, MCW etc, make it very difficult for this Company to engage in conventional PR

Trevor Brown has served as the Chief Executive Officer (CEO) of IQ-AI Limited, the parent company of Imaging Biometrics, LLC, for the past two years (2023–2025). In this role, he has provided strategic oversight for IQ-AI and its subsidiaries, including Imaging Biometrics, which focuses on delivering quantitative imaging platforms and therapeutics for enhanced clinical diagnosis and treatment. Key aspects of his role include:

Leadership and Strategic Direction: Brown has guided IQ-AI’s efforts in advancing medical imaging technologies and therapeutics, particularly in oncology and neurology. He has been instrumental in overseeing the company’s focus on innovations like the Phase 1 clinical trial of gallium maltolate (GaM) for glioblastoma treatment at the Medical College of Wisconsin.

Financial and Regulatory Contributions: He has played a significant role in securing funding for clinical trials, including financial support for the GaM Phase 1 trial and plans for a Phase 2 trial. Brown has also been involved in pursuing regulatory milestones, such as FDA Fast Track designation and Orphan Drug designations for GaM.

Public Statements and Advocacy: Brown has been a vocal advocate for Imaging Biometrics’ technologies, frequently commenting on their impact, such as the deployment of IB’s software at Insel Gruppe AG in Switzerland and its integration with Bayer’s Calantic™ platform. He has highlighted the potential of GaM to extend survival rates in glioblastoma patients and the company’s efforts to secure FDA Breakthrough Therapy Designation.

Throughout this period, Brown’s role has centered on driving IQ-AI’s mission to transform clinical diagnostics and treatment through advanced imaging solutions and strategic partnerships, while navigating financial and regulatory landscapes to support the company’s growth.

I count 10 RNSs issued in that last 12 months, nearly one a month, yet some here say the company doesn't communicate with shareholders. Also reading the public information available from third party sources about the various projects, amounts to a staggering amount of coverage. Mentions in Papers and Publications (June 28, 2024 – June 28, 2025):

Neuroradiology Study (May 10, 2024): A study published in Neuroradiology validated the benefit of IB Rad Tech for distinguishing treatment effects in brain tumors. This counts as one mention of Imaging Biometrics.

American Journal of Neuroradiology (March 12, 2024): A study published in the American Journal of Neuroradiology highlighted Imaging Biometrics’ work, specifically its quantitative imaging solutions. This is another mention.

Nature Communications (October 18, 2023): A landmark study in Nature Communications featured Imaging Biometrics’ dynamic susceptibility contrast (DSC) MRI software for characterizing high-grade glioma.

Kaneonaim, interested in your assessment of this being a 'lifestyle' company. How is this notion supported by the facts? All the insiders have seen the value of their shareholdings fall to a tiny fraction of what they were, I don't know how many shares you own, but I suspect you are not showing a loss of millions of pounds like some. One problem is that the small company market now barely exists for serious investors, there appear to be mainly gamblers (see recent bitcoin treasury madness for example) and here people demonising the board members and offering simplistic and naive solutions rather than thinking what might actually be the problem, the main one being the 'macro' - the almost zero interest in micro caps. amongst real investors

Tyke, what is interesting is how few people are apparently following this thread. Looking below, 5 votes only were garnered in judging TEB's efforts as negative. Of course there could be a massive silent majority who adore him. It would be useful to ask everybody who follows the threads to 'recommend' your survey?

If you put up an IQAI chart for 2019-2021 you will see two remarkable spikes, mysterious and unexplained, and before all that has happened since, including the trial - which wasn't even a gleam in the eye of any then shareholder. Then there was the long unwinding of one the old Flying Flowers stalwarts, West Coast, which coincided (?) with a period of share price weakness in subsequent years. Now there is no history, IBAI is only days old and we are at chart Zero. Anyone coming to this company for the first time will be neither advantaged nor disadvantaged by the share price history as the historic chart will be silent. As to the 'shenanigans' so often fondly referred to as an explicator for what is perceived to be a low share price, after so much time and lack of visibility, "Trevor who?", maybe we now have an embryo with a lifetime ahead?

Friday again Tyke, It just flew past. One significant restraint on the kind of publicity and promotion you are calling for is that the combined effect of FDA, FCA, medical ethical, disclosure rules and regulations can mean the choice is between a meatless anodyne Reach type communication and silence.

Have a good weekend everybody

I asked AI what role IQAI had in the trial to get an independent perspective

IQ-AI, Ltd., through its wholly owned subsidiary Imaging Biometrics, LLC, plays a multifaceted role in the Phase I clinical trial evaluating Gallium Maltolate (GaM) for the treatment of Glioblastoma Multiforme (GBM) at the Medical College of Wisconsin (MCW). Their contributions include:

1. Funding: IQ-AI provides financial support for the trial, which is critical for its execution. They have also expressed intent to contribute significantly to the costs of a planned Phase II trial.

2. Imaging Technology: The trial utilizes Imaging Biometrics’ FDA-cleared IB Neuro™ and Delta T1™ neuroimaging platforms to quantitatively monitor tumor volumes and assess treatment efficacy. These tools have been widely used in multi-center clinical trials for brain tumor treatments.

3. Regulatory Strategy: IQ-AI is actively involved in pursuing regulatory pathways to accelerate GaM’s potential market approval. This includes securing Orphan Drug Designation from the FDA for GaM in both adult and pediatric GBM populations, which can expedite development for rare diseases. They also plan to enlist regulatory experts to leverage programs like the Orphan Drug program if trial outcomes are promising.

4. Expanded Access Program (EAP): IQ-AI, via Imaging Biometrics, sponsors an FDA-approved EAP for GaM, making it available to patients with relapsed/refractory GBM who cannot enroll in the Phase I trial and have exhausted standard treatments. This program is facilitated through xCures and aims to provide hope while gathering additional data.

5. Strategic Oversight: IQ-AI’s leadership, including CEO Trevor Brown and Imaging Biometrics’ CEO Michael Schmainda, is actively engaged in advancing GaM’s development, as evidenced by their public statements and plans for presenting GaM at scientific conferences.

In summary, IQ-AI is a key stakeholder, providing funding, proprietary imaging technology, regulatory strategy, and support for expanded access, all of which are integral to the trial’s progress and the potential advancement of GaM as a novel GBM therapy.

Https://www.lse.co.uk/rns/IQAI/iqai-commits-to-phase-1-study-obuj1w6y92fc1ur.html

No weekend wished from Tyke, hope all is well in Tykeland

What do I know about the share transactions today, not more than anyone else, but I have a perspective to share which may or may not be correct. There was a recent share placing. Many placees will have been motivated by the prospect of a quick flip of the shares at the subscription price plus a whisker. It became impossible to sell on at a profit after the placing, leaving many stranded bulls. The supply we see this morning and recently is likely from this pool. If I am correct, it is a limited supply, they are likely to provide resistance up to their subscription price until they are cleared. Note to meaning seekers, if I am correct any news will be irrelevant to them beyond providing some demand to help with their quest to get out. End of.

Its an attempt to establish whether the view of some here, that the CEO may be a deterrent to share buyers is objectively likely or not, presumably an AI view would come close to the general perception of potential and existing shareholders?

I note the preoccupation with Trevor Brown continues. A suggestion for those of you who re still fixated - use AI to provide an answer to the question : "What has been the consequence of having Trevor Brown as CEO of IQAI. Has he made a material difference to the prospects and success of the Company? "

There must be more interesting questions to discus about IQAI's future prospects than its CEO

A rose by any other name.....

Tyke, most micro caps, raise money as cheaply and as conveniently as possible via a placing. Experience shows that very few existing shareholders are interested in adding shares and then usually mostly in tiny amounts (look at the average bargain size in IQAI). The only practicable way is to 'market sound' i.e. establish what the demand for shares would be at a certain price to raise a certain sum. Sometimes the offer is left open via a brokers option, but you would be surprised at how little real interest there is. Talk is cheap as they say. Usually the support of the largest shareholder in the placing is essential to ensure success. One of the first questions asked by prospective placees is 'is the BOD or major shareholders participating' Why should placees put up cash if the board or majors are unwilling. The fact that it was possible after the placing to buy shares at .85p (a 15% discount to the placing price) but barely any bargains were done at this price is an indication of the real retail demand for shares. However even so, some here believe it somehow advantaged of certain persons to participate in the placing where the shares are already trading at less than the placing price. This was also the pattern in last years placing where all placees are now showing a 70%. loss.

xviolet There has been a large amount of news and communication and promotion, e.g. videos and podcasts, as well as RNS by the board over past months and years, arguably more than the average small cap.

Max, consider the macro, the quantitative easing from 2008-21 resulted in huge liquidity pouring into small and smaller cap stocks propelling to an unsustainable level. For many investors this was the norm. So buying 3-12 years ago meant paying a super premium. As micro caps corrected, in some cases the correction is already over done. But remember these small caps were never bought for investment reasons, they were propelled not by fundamentals but too much hot cash looking for a home because the alternative was zero interest rates. In any discussion this fundamental context must be acknowledged. Even now there is almost no rational discussion in these threads. Punters simply have no idea about the relationship between earnings (often there are any) and discounted future flows if revenue, pe ratios, eps, nav etc. Posts are generally paranoid and stupid, this drives out intelligent thoughtful minds and though there are one or two here not braindead, they soon leave because what is the point....